Investors
FAQ
What is AXIM Biotechnologies, Inc.'s stock symbol?
Our stock is traded on the OTCQB under the symbol AXIM.
How can I buy AXIM shares?
You can buy AXIM shares through a broker, just as you would other securities.
How can I keep up to date with latest developments at AXIM?
You can register to receive updates announced by AXIM by submitting your email address in Email Alerts on the Investor Relations section of our website.
When was AXIM Biotechnologies, Inc. incorporated?
2010
When did AXIM Biotechnologies, Inc. become a public company?
March 2014
Where is AXIM Biotechnologies, Inc. located?
6191 Cornerstone Court, E., Suite 114,
San Diego, CA 92121
When is AXIM Biotechnologies, Inc.'s fiscal year end?
December 31st
Who is AXIM Biotechnologies, Inc.'s transfer agent?
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com
Who is AXIM Biotechnologies, Inc.'s independent auditor?
RBSM LLP
805 Third Avenue
Suite 902
New York, NY 10022
T: 212-868-3669
www.rbsmllp.com
Who is AXIM Biotechnologies, Inc.'s outside legal counsel?
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA 92024
T: 858-229-8116
pek@peklaw.com
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM...
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
Partner News: Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform Business Wire TAMPA, Fla. -- July 25, 2023 Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value...
